#Sepsis is still a leading cause of worldwide mortality among children. Learn more about the facts of pediatric sepsis and how it can be diagnosed during pediatric sepsis week: https://bit.ly/3UlRuOc
Immunexpress Inc.
Biotechnology Research
Seattle, Washington 1,774 followers
We are pioneering the technology that analyzes the immune system to rapidly detect sepsis.
About us
Immunexpress is a privately owned company creating revolutionary molecular diagnostics for sepsis. The company has offices in Seattle, USA and Brisbane, Australia. Immunexpress's product pipeline aims to address the overwhelming unmet clinical needs of sepsis patients, as well as clinicians, payers and healthcare systems. Unlike the traditional approach to sepsis diagnosis, SeptiCyte® quantifies the specific molecular biomarkers from a patient's immune system ('host response'). Biomarkers capture signals from a patient's immune system in response to infection. These biomarkers may hold the key to early detection of sepsis, as well as guiding the use and timing of drugs and other therapies.
- Website
-
http://immunexpress.com
External link for Immunexpress Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Seattle, Washington
- Type
- Privately Held
- Founded
- 2006
- Specialties
- Medical devices, Molecular diagnostics, and Sepsis
Locations
-
Primary
Get directions
425 Pontius Ave N
Suite 430
Seattle, Washington 98109, US
Employees at Immunexpress Inc.
-
Thomas Yager
Sr. Director, Research & Development at ImmuneXpress Inc
-
Jane (Markley) Papadaki
VP of Market Development & Commercial Operations at Immunexpress Inc.
-
Carol Whisenant
Office Manager and Executive Assistant at Immunexpress Inc
-
Greg Uhl
Director Finance at Immunexpress Inc.
Updates
-
Hope to see you tomorrow at the Houston Methodist Research Institute for the International Symposium on Advances in Critical Care Medicine (ISAC) 2024, a vital forum for the latest information in critical care medicine. Visit our exhibit to learn more about #sepsis testing and SeptiCyte® RAPID. Learn more here: https://bit.ly/444vcDL
-
-
Immunexpress today announced its participation at ESCMID - European Society of Clinical Microbiology and Infectious Diseases Global, where two independent presentations will showcase the performance of SeptiCyte® RAPID in ICU patients. Investigators from Nantes Université and Universitätsklinikum des Saarlandes will present findings. Read the news release here: https://prn.to/49He1JG
-
-
Join us in celebrating the laboratory professionals who make valuable contributions to the health of our families, friends, and communities during the 49th annual Medical Laboratory Professionals Week. Learn more: https://bit.ly/49xkZkw #LabWeek
-
-
Not to be missed! Be sure to stop by posters P0959 and P3895 at ECCMID to learn more about how the SeptiCyte® RAPID assay performs in critical care settings. ESCMID - European Society of Clinical Microbiology and Infectious Diseases
-
-
Get Ready! Immunexpress will be attending the International Symposium on Advances in Critical Care in Houston, Texas, from April 19-20. Register today: https://bit.ly/3xk4VVS
-
-
#Sepsis is a dangerous but surprisingly common condition that affects 1.7 million adults in the U.S. each year, according to the Centers for Disease Control and Prevention. Learn more here: https://lnkd.in/egfybbe
-
-
See you in Barcelona! With ECCMID right around the corner, make sure to visit posters P0959 and P3895 to learn more about the performance of our SeptiCyte® RAPID assay. ESCMID - European Society of Clinical Microbiology and Infectious Diseases
-
-
#Sepsis is a worldwide crisis, but especially impacts lower income countries, which accounted for 85% of all cases and related deaths according to the World Health Organization. Learn more here: https://bit.ly/42U6WUs
-